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ABSTRACT
The immune environment present after allogeneic hematopoietic stem cell transplantation (HSCT) contributes to
the control of leukemia. Our laboratory has demonstrated in a murine model that vaccination of recipients after
transplantation with recipient tumor vaccines does not exacerbate graft-versus-host disease but does induce
meaningful graft-versus-tumor effects. We previously demonstrated that part of the reason for the lack of graft-
versus-host disease from post-transplantation vaccination is due to gradual acquisition of tolerance or unrespon-
siveness to recipient immunodominant minor histocompatibility antigens that are ubiquitously expressed in the
recipient. However, our prior studies have not critically addressed the question of whether a similar process of
acquisition of unresponsiveness to or tolerance of antigens present on minimal residual disease also occurs. The
present study tested the hypothesis that unresponsiveness to antigens present on minimal residual disease present
at the time of HSCT would also occur. The answer to this question would have a significant effect on the potential
efficacy of post-transplantation tumor vaccines. In a murine model of major histocompatibility complex matched,
minor histocompatibility antigen mismatched HSCT (C3.SW female donors and C57BL/6 female recipients), we
tested whether transplant recipients would acquire unresponsiveness to antigens present on small numbers of
residual leukemia/lymphoma cells. We employed a male C57BL/6 lymphoid malignancy with an immunoglobulin/
c-myc oncogene in these studies using as a model of tumor-restricted antigen the well-characterized male (HY)
antigen system present only on the tumor but not present as ubiquitous minor antigens in the recipient. After
HSCT, recipients did not mount immune responses to the ubiquitously distributed immunodominant recipient
strain H7 minor histocompatibility antigen, but did retain the capacity to mount significant T cell responses to HY
antigens present on small numbers of HY tumor cells present at transplantation. Additional studies using small
numbers of nonmalignant recipient male B cells or dendritic cells as models of minimal residual disease also
demonstrated that the transplant recipients retained their capacity tomount anti-HYT cell responses. AfterHSCT,
recipients may retain the capacity to mount effective T cell responses to antigens present on minimal residual
disease and still acquire relative tolerance to ubiquitously distributed immunodominant minor antigens that are
related to graft-versus-host disease.
© 2007 American Society for Blood and Marrow Transplantation
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dNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (HSCT) is performed for treatment of some d
4igh-risk leukemias and lymphomas. In general, pa-
ients are in remission or in a state of minimal residual
isease at time of transplantation. Clinical studies have
emonstrated that immunologic processes contribute
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MRD Tolerance 35o serious toxicity in the form of graft-versus-host
isease (GVHD) and to cure in the form of graft-
ersus-tumor or graft-versus-leukemia (GVL) effects.
linically, it has been difﬁcult to separate the 2 effects.
n important goal is to deﬁne methods by which GVL
s maximized and GVHD is minimized. Our labora-
ory has been investigating whether tumor vaccines
an enhance GVL without offsetting exacerbations of
VHD.
In most allogeneic major histocompatibility com-
lex (MHC)-matched HSC transplant recipients, im-
unosuppressant drugs given to prevent GVHD can
e discontinued 2 to 6 months after transplantation. In
uch cases the allogeneic graft has developed tolerance
o widely distributed host minor histocompatibility
ntigens. We have demonstrated that cellular tumor
accines can be administered after transplantation
ithout worsening of GVHD in a murine model of
HC-matched, minor histocompatibility antigen
mHA)-mismatched transplantation. Moreover, the
ork has demonstrated that antitumor immune re-
ponses can be induced and that vaccine-treated trans-
lant recipients exhibit prolonged survival when chal-
enged with tumor [1-3]. One interpretation of these
ndings is that the post-transplantation immune sys-
em has acquired tolerance of widely distributed mHA
ut is not tolerized to other antigens on tumor.
A question that is unresolved by this work is
hether the donor immune system could also develop
olerance to tissue or tumor-restricted antigens present
n the minimal residual tumor present in the host at the
ime of transplantation and throughout the early post-
ransplantation period when tolerance to widely ex-
ressed mHAs is being acquired. If the host acquires
olerance to antigens present on minimal residual leu-
emia, then vaccines would not be effective in con-
rolling minimal residual disease. Conversely, if the
ngrafting immune system retains the potential to
espond to antigens on minimal residual disease, ex-
loration of post-transplantation vaccines for aug-
entation of GVL effects may be worthwhile.
We tested the hypothesis that the engrafting do-
or immune system acquires tolerance to antigens
resent on minimal residual disease. We employed a
odel of MHC-matched, mHA-mismatched trans-
lant in which female C3.SW mice were donors for
emale C57BL/6 recipients. We used male C57BL/6
eukemia/lymphoma cells and nonmalignant male
57BL/6 cells as models for minimal residual disease
ecause male cells have several well-characterized
HAs encoded by genes on the Y chromosome (HY
ntigens) [4]. In this setting immune responses to
olecularly characterized HY antigens present on the
ale cells could be assessed and differentiated from
mmune responses to the mHAs distributed widely in
he tissues of the transplant recipient [5]. In this trans- ilantation model, the immunodominant H7a antigen
s expressed in all recipient tissues [6].
ETHODS
ouse Strains
Female C3.SW-H2b/SnJ mice (Jackson Labora-
ory, Bar Harbor, Me) were donors and female
57BL/6 mice (National Cancer Institute, Frederick,
d) were recipients. The mice are MHC antigen
atched (H2-b) and mHA mismatched at many loci
H1, H3, H8, H9, H13, H7a-B6dom1). C3.SW mice
re H-2b and were derived from an 11-generation
ackcross of C3H against a non-inbred H-2b donor
train [7]. C57BL/6 are Mls null. For experiments
ith MHC II-deﬁcient cells, B6;129S-H2dlAb1-Ea
ice (Jackson Laboratory) were used. They are ho-
ozygous null for the MHC class II genes H2-Ab1,
2-Aa, H2-Eb1, H2-Eb2, and H2-Ea [8].
one Marrow Transplantation
Total body irradiation was administered with a
obalt 60 source; 1100 cGy of external gamma irradi-
tion was given to recipients in 2 equal divided doses,
4-16 hours apart, on days 1 and 0. For normal
ransplants containing donor T cells, 4  106 bone
arrow (BM) cells plus 10  106 spleen cells (as a
ource of donor T cells) in 0.2 mL of Hank balanced
alt solution were injected intravenously. (Unlike hu-
an clinical BM products obtained by multiple per-
utaneous aspirations, murine BM has few T cells.)
hey were housed in conventional rooms with food
nd water ad libitum. From 2 days before BMT until
ay 14, water was acidiﬁed (pH 2.5) and supplemented
ith 2 g/L neomycin sulfate (Sigma, St Louis, Mo).
or experiments in which male B or T cells were
dded to the graft, magnetic positive selection using
aramagnetically labeled monoclonal antibodies for
D45R or CD3 were used (Miltenyi Biotec Auburn,
alif). We and other investigators have observed that
se of C3H.SW donors (with 5-10  106 T cells in
he graft) and C57BL/6 recipients produces fatal
VHD in a signiﬁcant number of recipients over a
-week period [9,10].
ell Lines
The B6-cmyc tumor lines are B lymphoblastic
umors that spontaneously arose in C57BL/6 trans-
enic mice that contained a human c-myc gene regu-
ated by an immunoglobulin promoter [11]. C1498
ATCC, Manassas, Va) is a spontaneous C57BL/6
cute NKT cell leukemia [12]. EL4 (ATCC) is a
57BL/6 lymphoma cell line [13]. The male acute
yeloid leukemia line is an early passage line obtained
rom a normal C57BL/6 male mouse that had been
ntravenously infused with normal male C57BL/6 BM
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A. Martinelli Natzke et al.36ells treated in vitro with retroviral vectors for a human
190 bcr/abl cDNA and a human Hox A9 cDNA [14].
mmunizations
To induce anti-HY T cell responses, female mice
ere subcutaneously injected with 107 25-Gy-irradi-
ted H2-matched male spleen cells. Vaccinations were
epeated at 2-week intervals. In a limited number of
xperiments, dendritic cells were used to vaccinate
nimals. To generate dendritic cells, murine marrow
as depleted of CD4 and CD8 T cells, B cells, and Ia
ells using monoclonal antibodies and magnetic sep-
ration (Miltenyi Biotec). Remaining cells were cul-
ured at 1  106 cells/mL for 6-7 days in murine
ranulocyte-macrophage colony-stimulating factor
1000 U/mL) and interleukin 4 (1000 U/mL). For
ome groups, dendritic cells were incubated overnight
n 100 g/mL of cell lysates produced by rapid freeze-
haw cycles in Hank balanced salt solution. Dendritic
ells were assessed by conventional microscopy and
ow cytometry using monoclonal antibodies for
D86 and CD11b; 2  105 dendritic cells were in-
ected subcutaneously for each vaccination.
ytotoxic T Lymphocyte Assay
Recipient splenocytes (effectors) were crushed us-
ng sterile glass slides. Erythrocytes were lysed using
CK erythrocyte buffer (0.15 M NH4Cl, 1.0 mM
HCO3, 0.1 nM ethylene-diaminetetra-acetic acid,
2O) and leukocytes were stimulated with irradiated
ale SW splenocytes (stimulators). Effectors and stim-
lators were placed in vitro at a 1:1 ratio at a concen-
ration of 107 cells/mL of R10S medium (RPMI, 10%
etal calf serum, 200 mM glutamine, 104 U/mL pen-
cillin/streptomycin, nonessential amino acids [1 mL/
00 mL of medium], 100 mM Na pyruvate, 50 mM
-mercaptoethanol). The cultures were incubated at
7°C for 5 days. Target cells were prepared by pulsing
hem with 1 mg/mL of HY peptides (Uty or Smcy).
argets were incubated with chromium 51 for 1 hour
t 37°C. Effectors were added to the targets and in-
ubated at 37°C for 4 hours. Chromium 51 release was
easured using a gamma counter. Percent lysis was
alculated using the following equation: %lysis 
(CPM  spontaneous lysis)/(maximum lysis  spon-
aneous lysis)]  100.
NZYME LINKED IMMUNOSPOT
Millipore HA 96-well plates (Billerica, MA) were
reincubated with anti-interferon- antibody at 10
g/mL in phosphate buffered saline. Plates were stored
t 4°C overnight. Plates were washed and blocked for
2 hours at 37°C with sterile phosphate buffered saline
nd 10% fetal bovine serum. In addition, 106 effector
ells were added to each well and stimulated with Uty
eptide (3 g/well) or left untreated. Cells incubated for l8 hours at 37°C. Interferon- release was detected by
ashing the wells and adding 1 g/mL of biotinylated
nti-interferon- antibody (Caltag, Burlingame, Calif).
fter 1 hour, streptavidin peroxidase (1:1000) was
dded to the wells and incubated at room temperature
or 30 minutes. Wells were washed and AEC substrate
AEC tablet, Sigma; 2.5 mL dimethylformamide, 47.5
L acetate buffer, 20 L 30% H2O2) was added to
ach well. Plates were then incubated for 5 minutes at
oom temperature in the dark and the reaction was
topped by rinsing the plate with water. Spots were
ounted after the plates dried.
nzyme-linked Immunosorbent Assay
Effector cells (106) were stimulated in vitro with or
ithout peptide (3 g/well) for 2 days at 37°C. Cyto-
ine concentrations were measured in the supernatants
ccording to the manufacturer’s protocols (Pharmingen,
an Diego, Calif ).
eptides
The amino acid sequences of the peptides used in
he experiments are H7a, AAPDNRETF [6]; Uty,
MHHNMDLI [15]; and Smcy, KCSRNRQYL [16].
tatistics
Prism 4.0 (GraphPad Software, Sorrento, Calif )
as used for statistical evaluation of data. Kaplan-
eier graphs were used to display survival and
urves were compared with a log-rank procedure.
hi-square tests were used to compare binary re-
ults. Enzyme-linked immunosorbent assay (ELISA) ex-
eriments with multiple groups were analyzed by 1-way
nalysis of variance followed by Tukey multiple com-
arison tests. Student t tests were used to compare
verage values in enzyme linked immunospot (ELIS-
OT) and cell lysis assays.
ESULTS
raft-versus-Tumor Effects against B Cell
alignancies Are Observed in Mice Undergoing
llogeneic Transplantation
In our previously published studies, we demon-
trated that vaccination after BM transplantation
BMT) enhanced graft-versus-tumor immune re-
ponses and survival in 2 murine cancer models [1]: a
pontaneously arising NKT cell leukemia (C1498) and a
hemical carcinogen induced ﬁbrosarcoma (205). We
ished to test the hypothesis that allogeneic graft-ver-
us-tumor activity with or without tumor vaccination
ould be associated with prolonged survival in other
pontaneous lymphoid malignancies. Kovalchuk et al
11] developed a model of spontaneous high-grade B cell
eukemia/lymphoma by producing a C57BL/6 trans-
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MRD Tolerance 37enic strain that expresses a human c-myc gene under
he inﬂuence of an immunoglobulin promoter. These
ice spontaneously develop high-grade B cell ma-
ignancies whose phenotype is very similar to hu-
an Burkitt-type B cell malignancies. From this
aboratory we acquired B lymphoblast lines from
ale and female mice to determine if in these ma-
ignancies an allogeneic graft-versus-tumor effect
ould enhance the immune resistance of allogeneic
ransplant recipients to challenge with tumor cells.
umor-free female C57BL/6 mice underwent trans-
lant using MHC-matched, mHA-mismatched female
3.SW donors. After engraftment cohorts of mice
eceived a series of vaccinations with irradiated B
eukemia/lymphoma cells. At the time of the third
accination (approximately 10 weeks after transplan-
ation), mice were challenged intravenously with live
leukemia/lymphoma cells. Survival was compared
cross (1) normal C57BL/6 mice, (2) C57BL/6 mice
hat had undergone allogeneic transplantation, and (3)
llogeneic transplant recipients that were also receiv-
ng post-transplantation vaccinations. Figure 1 shows
independent experiments involving a female B cell
eukemia/lymphoma (top panel) and a male B cell
eukemia/lymphoma line (bottom panel). In both ex-
eriments allogeneic transplant recipients had higher
urvival rates compared with nontransplanted mice
P  .01), an observation compatible with an alloge-
eic effect. In experiment 1 the observed prolonged
urvival in the vaccine-treated group did not reach
tatistical signiﬁcance compared with the group un-
ergoing allogeneic transplantation without vaccina-
ion (P  .29). In experiment 2 the group receiving
ost-transplantation vaccinations had prolonged sur-
ival compared with mice that had undergone alloge-
eic transplantation but no subsequent immunization
P  .01). Animals that died had diffuse malignancy
ith splenomegaly, lymphadenopathy, and BM lym-
hoblasts. Survivors did not exhibit macroscopic signs
f severe GVHD (wasting, rufﬂed fur). (Histologic
nalysis was not performed and thus subclinical
VHD in lymphoma survivors could not be ex-
luded.) These experiments were consistent with our
rior observations in the other tumor models.
llogeneic BM Transplant Recipients Receiving
mall Numbers of HY Malignant B Lymphoblasts
t Time of Transplantation Are Not Tolerized,
ut Mount Strong Immune Responses to Later
accination with HY Cells
Our prior work using other tumor models had
emonstrated that vaccination of BM transplant re-
ipients with tumor cells did not induce T cell re-
ponses to the immunodominant mHA H7a expressed
n both tumor cells and all C57BL/6 tissues, despite
he fact that the C3.SW donor strain generates robustcell responses to H7a [2,5,6,17-19]. We extended whese studies by examining immune responses to H7a in
M transplant recipients after vaccination with B6-cmyc
ells. We included a cohort of BM transplant recipients
hat had small numbers (103) of viable male B6-cmyc
ells mixed with the hematopoietic cells infused at
ime of transplantation. Starting 1 month after trans-
lantation mice were vaccinated with irradiated
57BL/6 spleen cells that express the H7a antigen.
LISA for interferon- release in response to H7a
eptide was then performed (Figure 2). As expected,
he positive control normal C3.SW mice vaccinated
igure 1.Mice undergoing allogeneic bone marrow transplantation
BMT) exhibit prolonged survival. Female C57BL/6 mice under-
ent allogeneic BMT using C3.SW donors. Approximately 6 weeks
ater, 1 cohort started a regimen of vaccination with 5  106
rradiated B6-cmyc lymphoma cells. Mice were injected subcutane-
usly weekly for 4 weeks and then every 2 weeks until completion
f the experiments. At the time of the third vaccination, mice were
nfused intravenously with 1  104 live lymphoma cells. Mice were
ollowed for survival. Lymphoma cells from a female (top) and male
bottom) were used for vaccination and challenge. The following
values were determined: experiment 1, BMT and vaccine versus
o BMT, P  .011; experiment 1, BMT and no vaccine versus no
MT, P  .005; experiment 1, BMT and vaccine versus BMT and
o vaccine, P  .28; experiment 2, BMT and vaccine versus no
MT, P  .0001; experiment 2, BMT and no vaccine versus no
MT, P  .007; experiment 2, BMT and vaccine versus BMT and
o vaccine, P  .01. P values were generated using a Kaplan-Meier
urves and log-rank procedure.ith the C57BL/6 spleen cells had a robust interfer-
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A. Martinelli Natzke et al.38n- response (P  .01 versus all other groups). In
ontrast, vaccinated C57BL/6 BM transplant recipi-
nts of C3.SW grafts did not generate an H7a-speciﬁc
nterferon response. Similarly, BM transplant recipi-
nts that had also received small numbers of male
6-cmyc cells did not a generate H7a response to
accination with C57BL/6 spleen cells.
One hypothesis for this lack of response is that the
onor immune system acquires relative tolerance to
he host H7a antigen because of persistent exposure to
ost mHA ubiquitously expressed in the recipient. We
ested this in strain-matched but sex-mismatched
ransplantation of female C57BL/6 cells into male
57BL/6 recipients (in which HY is ubiquitously ex-
ressed). Some transplant recipients were vaccinated
ith male C57BL/6 spleen cells. If exposure to ubiq-
itous HY would induce unresponsiveness, then trans-
lant recipients would not generate an anti-HY T cell
esponse. Figure 3A demonstrates that male recipients
f female grafts did not generate anti-HY cytolytic
esponses, whereas normal female C57BL/6 mice did.
he hypothesis was tested in a second model: trans-
lantation of female C3.SW cells into male or female
igure 2. Vaccination of recipients after bone marrow transplan-
ation (BMT) does not induce a type I interferon- (IFN-) re-
ponse to the ubiquitous immunodominant minor histocompatibil-
ty antigen H7a. C57BL/6 female mice received allogeneic BMT
sing C3.SW donors (SW). Some mice also received approximately
 103 live male B6-cmyc lymphoma cells intravenously with the
raft (MRD). Four weeks after transplantation, mice were vacci-
ated subcutaneously with 107 irradiated female C57BL/6 spleen
ells (Vac). Three vaccinations were performed at 10-day intervals.
en days after the ﬁnal vaccination, splenocytes were harvested and
nzyme-linked immunosorbent assay for IFN- was performed.
alues displayed represent INF produced by wells stimulated with
7a peptide minus IFN released in wells not stimulated. One-way
nalysis of variance was used to analyze enzyme-linked immunosor-
ent assay results with subsequent pair comparisons using a Tukey
ultiple comparison test.57BL/6 recipients. In the male recipients HY anti- iens would be ubiquitously expressed, as would the
train-speciﬁc mHA, H7a. In contrast, in female trans-
lant recipients HY would not be ubiquitously ex-
ressed, whereas H7a would. Animals were then vac-
inated with irradiated male myeloid leukemia cells and
LISPOT assays for interferon release were performed.
igure 3B shows that vaccinated female transplant recip-
ents mounted responses against HY antigen but not the
llogeneic H7a antigens. In contrast, vaccinated male
ransplant recipients did not mount responses to HY
ntigen or the allogeneic H7a antigen.
We then performed experiments to test the hy-
othesis that BM transplant recipients that received
iable minimal residual disease cells during the period
f engraftment would also be unresponsive to vacci-
ation against antigens expressed on the minimal re-
idual malignant cells. Female C57BL/6 mice under-
ent allogeneic transplantation using C3.SW donors;
ecipients also received small numbers of viable B6-
myc malignant cells. After engraftment mice were
accinated with C3.SW dendritic cells loaded with
ysates of male B6-cmyc lymphoblasts. To measure
mmune response to HY antigen, ELISA was per-
ormed using the peptide epitope of the male Smcy
ene. Responses of individual mice were assessed. Fig-
re 4 demonstrates that HY-speciﬁc responses oc-
urred in 50% of the vaccinated BM transplant recip-
ent mice that had been exposed to B6-cmyc cells
uring engraftment (P  .05). In contrast, none of the
ice that had been exposed to male B6-cmyc cells
uring engraftment but not later vaccinated generated
n HY-speciﬁc response.
In other experiments HY-speciﬁc cytolytic T
ell responses were measured in chromium release
ssays using female C57BL/6 cells exogenously
oaded with male HY peptide. Figure 5 represents 2
ndependent experiments. HY-speciﬁc cytotoxic T
ymphocyte (CTL) responses were seen in vacci-
ated BM transplant recipients that had been ex-
osed to minimal residual male B6-cmyc cells dur-
ng engraftment.
llogeneic BM Transplant Recipients Receiving
mall Numbers of Nonmalignant HY Male
Cells Mount Vigorous Immune Responses to
ater Vaccination with HY Cells
The B6-cmyc line is a high-grade B cell malig-
ancy that is tumorigenic in normal C57BL/6 mice at
ery low doses of cells. In the experiments reported
bove at the time of harvest, none of the mice had
linically evident tumor 2 months after transplanta-
ion. One likely explanation for this observation is that
he allogeneic immune response that occurs in the
eeks after transplantation produced an effective
VL response that eventually eradicated the malig-
ant cells. (This possibility is compatible with the data
n shown Figure 1 in which allogeneic transplant re-
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MRD Tolerance 39ipients not vaccinated after transplantation had better
urvival compared with nontransplanted C57BL/6
ice.) One could argue that, if transplant recipients
ere exposed to a larger number of HY-antigen pos-
igure 3. Lack of T cell responses to ubiquitously distributed alloan
nderwent BMT using female C57BL/6 donors. One month later
eekly vaccinations, cytolytic cell assays were performed using fem
emale and HY vaccine indicates cells from a normal female C57B
ecipients that did not receive vaccination after BMT with male s
accinated against male cells. Lysis of EL4 cells pulsed with (left) an
ysis at each effector-to-target (ET) ratio. Lysis of HY targets is
P  .05 by t test). B, Interferon (INF) ELISPOT assays in respons
57BL/6 mice underwent allogeneic transplantation using female C
ale C57BL/6 acute myeloid leukemia cells. After 3 weekly vaccina
hree to 9 replicates for each were performed based on cell availabili
ormal C3.SW female vaccinated, and normal female C57BL/6 m
esponses to H7a were seen only in C3.SW mice vaccinated with mtive cells during the period of engraftment, they gould acquire unresponsiveness to HY-associated an-
igens. However, it was not technically feasible to
nclude larger numbers of male B6-cmyc cells at the
ime of transplantation because rapid tumor growth
after bone marrow transplantation (BMT). A, Male C57BL/6 mice
ere vaccinated with irradiated male C57BL/6 spleen cells. After 3
7BL/6 target cells (EL4) pulsed with HY (Smcy) peptide. Normal
ce vaccinated with male splenocytes; BMT No vaccine, transplant
ytes; BMT & HY vaccine, cells from mice after BMT that were
out (right) HY Smcy peptide is presented, as are average and SEM
cally signiﬁcant only for the Normal female & HY vaccine group
and H7a antigens after allogeneic transplantation. Male or female
onors. One month later animals were vaccinated with 107 irradiated
LISPOT assays were performed against HY Uty or H7a peptides.
rage and SEM are plotted. For HY peptide female BMT vaccinated,
unted an IFN responses (P  .05 by t test). In contrast, positive
7BL/6 cells (P  .05 by t test).tigens
mice w
ale C5
L/6 mi
plenoc
d with
statisti
e to HY
3.SW d
tions, E
ty. Ave
ice moenerally resulted in mice having large tumor burden
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A. Martinelli Natzke et al.40t the time vaccination would start. This would not be
model of minimal residual disease. Rather, it would
e a study of effect of large tumor burden on immune
esponsiveness. Many investigators in many tumor
odels have demonstrated acquired unresponsiveness
r tolerance in the setting of advanced malignancy.
Using an alternative approach we performed ex-
eriments in which 2  106 nonmalignant male
57BL/6 B cells were added to the donor graft cells
nfused after completion of the preparative regimen.
lthough such recipient strain cells would also be
ubject to the donor allogeneic effect, we reasoned
hat the larger number of male cells might provide a
reater tolerizing effect than the smaller number of
igure 4. Recipients after bone marrow transplantation (BMT) that
eceive small numbers of live HY antigen positive B6-cmyc B
ineage lymphoblastic malignant cells at time of transplantation are
ot tolerized to vaccination with HY antigens after engraftment.
emale C57BL/6 mice underwent allogeneic BMT using female
3.SW donors. MRD groups also received intravenous nonlethal
oses of live male B lymphoma/leukemia cells mixed with the graft.
our weeks later some of the mice infused with HY B6-cmyc were
accinated 3 times at weekly intervals with C3.SW dendritic cells
hat had been incubated with lysates from male B6-cmyc cells.
nzyme-linked immunosorbent assay for interferon- was per-
ormed 1 week later using the male-speciﬁc Smcy peptide as the
timulus for cytokine release and animals were classiﬁed as respond-
rs or nonresponders. A positive response was a value 	2 SDs
reater than speciﬁc release in the no-MRD, no-vaccine group. The
roportion of animals responding to HY Smcy is plotted. N indi-
ates number of animals per group. The MRD & vaccine group had
signiﬁcantly greater proportion of responders (P  .05 by chi-
quare analysis). The mean interferon release among responders in
he vaccine-treated group was 1173 
 860 pg/mL (average 
 SD),
hereas the mean interferon release among nonresponders in the
accine-treated group was 44 
 57 pg/mL (P  .01 by t test). The
ean interferon release in the MRD group was 228 
 139 pg/mL,
hereas the mean interferon release no-MRD, no-vaccine group
as 88 
 137 pg/mL.ale B6-cmyc cells in the previous experiments. An- amals underwent allogeneic transplantation and some
eceived normal male C57BL/6 splenic B cells. One
onth later animals were vaccinated with male spleen
ells and subsequently assessed for generation of an-
imale T cell responses. Figure 6A presents the results
f chromium release assays using C57BL/6 female
ells with and without exogenous loading with male
Y peptide. Results were similar to those seen with
ecipients given small numbers of malignant B lym-
hoblasts. Animals that received normal male B cells
xhibited the strongest anti-HY CTL responses.
In other experiments we assessed the inﬂuence of
ale T cells on response to later vaccination. In con-
rast to the HY-speciﬁc priming we consistently saw
ith B cells, recipients of small numbers of male T
ells failed to consistently show HY-speciﬁc responses
o later vaccination (Figure 6B). Simultaneous transfer
f male B cells and male T cells did not eliminate the
pparent priming of B cells; nor did cotransfer of male
cells with male macrophages dampen the priming
nduced by macrophages (data not shown). B cells are
nown to be more effective antigen-presenting cells
han T cells, in part due to expression of MHC II
olecules. We repeated the experiments using class
I deﬁcient B cells to determine if class II expression
as necessary for the priming effect. However, re-
ipients of class II negative B cells still generated
trong anti-HY T cell responses after vaccination
data not shown).
M Transplant Recipients Receiving Small
umbers of HY Dendritic Cells Are Primed
gainst HY Antigens without Subsequent
accination
The failure to observe unresponsiveness to the HY
ntigens present on small numbers of residual male
ells may have been due to the fact that the antigens
ere not presented in an effective manner to the
ngrafting immune system. Evidence from other
ransplantation models has suggested that ubiquitously
xpressed minor antigens are best presented by residual
ost dendritic cells [10,20]. It is conceivable that the
ailure to observe tolerance to the HY-associated anti-
ens on the small numbers of malignant or nonmalig-
ant male cells was because the HY antigens in our
odel were not presented during the period of en-
raftment by dendritic cells. To test this we per-
ormed transplantations with some recipients being
iven male dendritic cells mixed with the female graft
ells. One group received dendritic cells that were not
ully mature and a second group received dendritic
ells that had been matured by incubation overnight in
he ﬁnal day of culture with male cell lysates. Some
nimals were subsequently vaccinated against male
pleen cells. Figure 7 presents the CTL activity
gainst female EL4 cells loaded with HY peptide and
gainst control EL4 cells without peptide. As in the
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MRD Tolerance 41ther experiments in which small numbers of male B
ells had been included with the graft, robust anti-HY
TL responses were seen in all groups that received
ale dendritic cells. However, in contrast to the other
xperiments, strong anti-HY responses were seen in
M transplant recipients that had received dendritic
ells but had not been subsequently vaccinated after
ngraftment.
ISCUSSION
The immune environment after allogeneic HSCT
s complex and dynamic. In most cases of MHC-
atched transplantation acute donor alloreactivity
gainst ubiquitously distributed host mHAs becomes
uiescent. In some systems alloreactivity associated
ith GVHD has been difﬁcult to separate from GVL
ctivity, and post-transplantation progression of ma-
ignancy has been temporally associated with loss of
lloreactivity [21]. We have demonstrated in our
ransplantation models that vaccination of allogeneic
ransplant recipients with whole host strain-derived
ellular tumor vaccines can induce meaningful antitu-
or responses without exacerbation of GVHD [1,3].
owever, if transplant recipients acquire immune un-
esponsiveness to antigens restricted to relatively
mall numbers of leukemia cells in a state of minimal
esidual disease, post-transplantation leukemia vaccines
igure 5. Mice undergoing bone marrow transplantation (BMT)
eukemia/lymphoma cells at time of transplantation can generat
ransplantation vaccination. Female C57BL/6 mice underwent all
ntravenous nonlethal doses of 103 live male B lymphoma/leukemia
rradiated male C3.SW cells subcutaneously 3 times at weekly in
erformed on splenocytes. Female EL4 cells with or without preload
xperiments. Killing of antigen-negative EL4 cells (left) and Smcy-p
ffector-to-target (E/T) ratios are plotted. MRD and vaccine group
P  .05 by t tests).ay be inherently ineffective. The experiments reported mere examined this issue. The experimental model used
ale HY antigens as a model for tumor-restricted anti-
ens, transferring small numbers of male cells (as a
odel of minimal residual disease) along with female
raft cells into female recipients.
Instead of observing impaired responses to HY
ntigens in transplant recipients, we observed that
nimals receiving small numbers of malignant male B
ymphoblasts actually manifested stronger CTL re-
ponses against HY antigens when vaccinated later
fter transplantation. This was in contrast to the very
oor immune responses these animals generated against
he immunodominant, widely distributed H7a mHA.
e examined the reproducibility of these observations
y substituting nonmalignant male B cells for malignant
ale B cells at the time of transplantation. Consistently
e observed that transplant recipients harboring rela-
ively small numbers of male cells had more robust
nti-HY T cell responses to vaccination than did mice
acking residual male cells. Together these experiments
o not support the hypothesis that the engrafting im-
une system generally becomes unresponsive to anti-
ens restricted to small numbers of malignant hemato-
oietic cells.
However, we did not observe the same degree of
riming to HY antigens when small numbers of male
cells were included in the transplant graft. This
aises the question of whether the transplant recipient
g small numbers of live HY antigen positive B6-cmyc B lineage
speciﬁc cytotoxic T lymphocytes (CTLs) in response to post-
BMT using female C3.SW donors. MRD groups also received
ixed with the graft. Vaccine-treated animals were injected with 107
starting 4 weeks after BMT. Two weeks later CTL assays were
h male HY Smcy peptide were targets. Figure shows 2 independent
EL4 cells (right) is shown. Average and SEM lysis at the speciﬁed
signiﬁcantly greater HY-speciﬁc lysis compared with other groupsreceivin
e HY-
ogeneic
cells m
tervals
ing wit
ositive
s hadight acquire unresponsiveness or tolerance to mini-
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A. Martinelli Natzke et al.42igure 6. Anti-HY T cell responses in vaccinated recipients after bone marrow transplantation (BMT) receiving live HY antigen positive male
or T cells at time of transplantation. A, Female C57BL/6 mice underwent allogeneic BMT using female C3.SW donors. Male B cell groups
lso received intravenous 2  106 live puriﬁed male B cells mixed with the graft. B, Independent experiment in which female C57BL/6 mice
nderwent allogeneic BMT using female C3.SW donors. Animals also received intravenous 2  106 live puriﬁed male T or B cells mixed with
he graft. Vaccine-treated animals were injected with 107 irradiated male C3.SW cells subcutaneously 3 times at weekly intervals starting 4
eeks after BMT. Two weeks later cytotoxic T lymphocyte assays were performed on splenocytes. Female C1498 cells with or without
reloading with male HY Uty peptide were targets. Killing of antigen-negative C1498 cells (right) and HY-positive C1498 cells (left) is shown.
verage and SEM lysis at the speciﬁed effector-to-target (E/T) ratios are plotted. Male B cell and vaccine groups had signiﬁcantly greater
Y-speciﬁc lysis compared with other groups represented in the graph (P  .05 by t tests), Male T cells and vaccine did not have signiﬁcantly
reater HY-speciﬁc cytolysis compared with the other groups (P 	 .05 by t test).
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MRD Tolerance 43al residual disease in some malignancies such as T
ell leukemia or lymphoma. We did not directly test
his hypothesis because we lacked a satisfactory male
cell leukemia model in this setting. Another possi-
ility for the difference observed is that transfer of
ale host T cells may have induced some degree of a
ost-versus-graft reaction that reduced the capability of
he graft to generate anti-HY responses. We did explore
hether simultaneous transfer of male T cells and male
cells or male T cells with male macrophages would
uppress the priming effect of minimal residual B cells or
acrophages, but observed that T cell responses to HY
accination were not impaired in such hosts (data not
hown). We did not assess to what extent the trans-
erred male T cells contained CD4CD25 Treg
ells; it is conceivable that such cells may account for
he differences we observed with male T cells.
Several models of post-transplantation regulation
f donor T cell responses to recipient antigens are
onsistent with our observation of loss of responses to
he ubiquitous immunodominant H7a mHA and pres-
rvation of responses to HY antigens. One model
upported by the work of Schlomchik et al [10] is that
ost strain antigen-presenting cells directly present
igure 7. Male dendritic cells (DCs) infused at time of transplan
nderwent allogeneic bone marrow transplantation (BMT) using fe
ixed with the graft. Mature DCs indicates DCs matured by overn
ncubated in lysates. (Flow cytometry for CD86 performed on the 2
hannel ﬂuorescence was 46 and that 16% of the cells were CD86
he mean channel ﬂuorescence was 107 and 42% of cells were CD86
roups were vaccinated with male splenocytes (top) or not vaccinate
L4 cells loaded with male HY Smcy peptide as targets or with EL4
ffector-to-target (E/T) ratios are plotted. At E/T ratios 50 lysis
y t test) for all groups except BMT only, no HY vaccination.he widely distributed host minor antigens (eg, H7a)o the incoming donor T cells. Initial activation of
lloreactive T cells produces an acute allogeneic re-
ponse driven by host APCs and which eventually
esults in donor T cell clonal exhaustion of cells ca-
able of responding to the mHA. In a model of min-
mal residual disease, the normal ubiquitous host
PCs still present after the conditioning regimen
ould not be able to directly present the HY-associ-
ted antigens. A second (and not mutually exclusive)
odel is that donor APCs process and indirectly
resent host antigens. On a simple quantitative, ana-
omic basis these donor APCs would be most active in
ost tissues subject to environmental inﬂammation
uch as skin, liver, and bowel (where the immunodom-
nant mHA would easily be found), although there
ight be a relatively small number of activated donor
PCs in tissues such as marrow or lymph nodes (less
ikely to be experiencing acute inﬂammation) where
he small numbers of residual male cells would be
ound. On a simple numerical basis this may result in
ery modest immune responses to HY cells leading
o priming, whereas high level presentation of ubiq-
itous mHA may result in clonal exhaustion or induc-
ion of immune suppression.
prime the recipient against HY antigen. Female C57BL/6 mice
3.SW donors. Some animals received 2  106 male C3.SW DCs
ubation with lysates of male splenocytes; immature DCs, DCs not
pulations demonstrated that in the less mature population the mean
red with the isotype control. In contrast, in the more mature cells,
a not shown.) BMT-only mice did not receive DCs. After 1 month
om). Cytotoxic T lymphocyte assays were performed using female
ithout peptide as a control. Average and SEM lysis at the speciﬁed
targets was statistically greater than lysis of HY targets (P  .05tation
male C
ight inc
DC po
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. Dat
d (bott
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of HYIn the study of allogeneic immune responses to
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A. Martinelli Natzke et al.44olid organ transplantations, it has frequently been
bserved that tolerance to allograft antigens can be
nduced when allogeneic hematopoietic stem cells are
lso given to the organ recipient [22-25]. Achievement
f hematopoietic macrochimerism often results in tol-
rance to organ alloantigens. One might speculate
hat this leads to a relatively high-level exposure of the
mmune system to alloantigens, leading to induction
f clonal exhaustion or suppression, similar to that
een in hematopoietic cell transplantation. In contrast,
olid organ tolerance is much less reliably induced
hen only hematopoietic microchimerism is induced
26-28].
In summary, these experiments explored whether
ecipients of allogeneic hematopoietic stem cell trans-
lants would acquire immune unresponsiveness to anti-
ens present on minimal residual disease. Our results
how this is not the case. This suggests that post-trans-
lantation vaccine therapy may be worthy of consider-
tion for enhancing the control of minimal residual dis-
ase. We speculate that the molecular identiﬁcation of
enes expressed at high levels in leukemia cells but not
biquitously expressed as host mHA may provide good
argets for vaccine therapy.
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